Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: EACarl who wrote (300)	1/11/2008 1:26:08 AM
From: tuck	Respond to of 684

>>Time to wake this thread up! ANDS now down to $1.44, last cash reported at $2.15. No debt, tangible BV $2.19.<< Yawn. Well, we know they have no product, so the question is can their cash reserves fund development of molecules to the point that they can be monetized -- at least to phase one. Do they have anything beyond P1? What's their burn rate on their preclinical stuff? I vaguely remember they have an interesting preclinical anti-infective program. What's their development strategy? Some decent deals have been done recently for P1 compounds (Intermune's HCV program, for instance). What's the chart say? Actually I was about to go to sleep. Be careful with the multiple posts. You're an old hand here on SI; you know that similar posts on 3 different threads is officially considered spam? Cheers, Tuck

To: EACarl who wrote (300)	1/11/2008 1:44:45 PM
From: Mike McFarland	Respond to of 684

I've considered buying back in several times, but have not--I'm not sure that the way they handled 975 was the best way to go about it. Biotech stocks crash all the time when a molecule fails, that is just part of the risk reward profile of the sector. But I wonder if Anadys dragged things along unusually long--which snared me. Now if you can find a chemist that says it looked all on the up and up... From last year this is the soft of thing they laid out for shareholders The recently initiated study, which utilizes a new crystalline form of ANA975 developed by Novartis, should further the understanding of the toxicology profile of ANA975 I think that the fellow who goes by the handle DueDiligence correctly sniffed out the trouble Anadys was in with that particular molecule. I wont speak for him further, but I suspect more astute biotech investors than myself knew the molecule was dead. I on the other hand love to play the contrarian and I found their press releases reassuring. Needless to say, I took a loss on ANDS. Presumably the management team is different now, but I think you could probably let a little more time elapse--maybe when the events of last summer are a good year behind them? They've changed CEO twice since then, right? Maybe that clears the board and maybe this is indeed the right time to get in, but I for one am staying clear of it, no matter the price. edit, now that I think about it, I did put ANDS into my biotech contest picks, ha! Message 24178745 But that is just because I've followed the story and it keeps it in my radar. I have two classes of stocks as my contest picks, speculative submicrocap stocks, and speculative biotechs price above $5 a share that have an air of respectability, heh. As I said, I've considered it for purchase in the real world, and passed, bwdik?